Therapeutic drug monitoring of old and newer anti-epileptic drugs
| LEADER | caa a22 4500 | ||
|---|---|---|---|
| 001 | 37891751X | ||
| 003 | CHVBK | ||
| 005 | 20180305123557.0 | ||
| 007 | cr unu---uuuuu | ||
| 008 | 161128e20041101xx s 000 0 eng | ||
| 024 | 7 | 0 | |a 10.1515/CCLM.2004.245 |2 doi |
| 035 | |a (NATIONALLICENCE)gruyter-10.1515/CCLM.2004.245 | ||
| 245 | 0 | 0 | |a Therapeutic drug monitoring of old and newer anti-epileptic drugs |h [Elektronische Daten] |c [Hugo M. Neels, Ann C. Sierens, Kristine Naelaerts, Simon L. Scharpé, George M. Hatfield, Willy E. Lambert] |
| 520 | 3 | |a The aim of the present paper is to provide information concerning the setting up and interpretation of therapeutic drug monitoring (TDM) for anti-epileptic drugs. The potential value of TDM for these drugs (including carbamazepine, clobazam, clonazepam, ethosuximide, felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, pheneturide, phenobarbital, phenytoin, primidone, tiagabine, topiramate, valproic acid, vigabatrin and zonisamide) is discussed in relation to their mode of action, drug interactions and their pharmacokinetic properties. The review is based upon available literature data and on observations from our clinical practice. Up until approximately 15 years ago anti-epileptic therapeutics were restricted to a very few drugs that were developed in the first half of the 20th century. Unfortunately, many patients were refractory to these drugs and a new generation of drugs has been developed, mostly as add-on therapy. Although the efficacy of the newer drugs is no better, there is an apparent improvement in drug tolerance, combined with a diminished potential for adverse drug interactions. All new anticonvulsant drugs have undergone extensive clinical studies, but information on the relationship between plasma concentrations and effects is scarce for many of these drugs. Wide ranges in concentrations have been published for seizure control and toxicity. Few studies have been undertaken to establish the concentration-effect relationship. This review shows that TDM may be helpful for a number of these newer drugs. | |
| 540 | |a © Walter de Gruyter | ||
| 690 | 7 | |a Medical equipment & techniques |2 nationallicence | |
| 690 | 7 | |a Medical diagnosis |2 nationallicence | |
| 690 | 7 | |a Diseases & disorders |2 nationallicence | |
| 690 | 7 | |a anti-epileptic drugs |2 nationallicence | |
| 690 | 7 | |a review |2 nationallicence | |
| 690 | 7 | |a therapeutic drug monitoring |2 nationallicence | |
| 700 | 1 | |a Neels |D Hugo M. |u Laboratory of Biochemistry and Toxicology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium |4 aut | |
| 700 | 1 | |a Sierens |D Ann C. |u Laboratory of Biochemistry and Toxicology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium |4 aut | |
| 700 | 1 | |a Naelaerts |D Kristine |u Department of Clinical Chemistry, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, Belgium |4 aut | |
| 700 | 1 | |a Scharpé |D Simon L. |u Laboratory of Medical Biochemistry, Universiteit Antwerpen, Antwerp, Belgium |4 aut | |
| 700 | 1 | |a Hatfield |D George M. |u Pharmacy, Island Hospital, Anacortes, WA, USA |4 aut | |
| 700 | 1 | |a Lambert |D Willy E. |u Laboratory of Toxicology, Ghent University, Ghent, Belgium |4 aut | |
| 773 | 0 | |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 42/11(2004-11-01), 1228-1255 |x 1434-6621 |q 42:11<1228 |1 2004 |2 42 |o cclm | |
| 856 | 4 | 0 | |u https://doi.org/10.1515/CCLM.2004.245 |q text/html |z Onlinezugriff via DOI |
| 908 | |D 1 |a research article |2 jats | ||
| 950 | |B NATIONALLICENCE |P 856 |E 40 |u https://doi.org/10.1515/CCLM.2004.245 |q text/html |z Onlinezugriff via DOI | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Neels |D Hugo M. |u Laboratory of Biochemistry and Toxicology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Sierens |D Ann C. |u Laboratory of Biochemistry and Toxicology, Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Naelaerts |D Kristine |u Department of Clinical Chemistry, Academisch Ziekenhuis, Vrije Universiteit Brussel, Brussels, Belgium |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Scharpé |D Simon L. |u Laboratory of Medical Biochemistry, Universiteit Antwerpen, Antwerp, Belgium |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Hatfield |D George M. |u Pharmacy, Island Hospital, Anacortes, WA, USA |4 aut | ||
| 950 | |B NATIONALLICENCE |P 700 |E 1- |a Lambert |D Willy E. |u Laboratory of Toxicology, Ghent University, Ghent, Belgium |4 aut | ||
| 950 | |B NATIONALLICENCE |P 773 |E 0- |t Clinical Chemistry and Laboratory Medicine |d Walter de Gruyter |g 42/11(2004-11-01), 1228-1255 |x 1434-6621 |q 42:11<1228 |1 2004 |2 42 |o cclm | ||
| 900 | 7 | |b CC0 |u http://creativecommons.org/publicdomain/zero/1.0 |2 nationallicence | |
| 898 | |a BK010053 |b XK010053 |c XK010000 | ||
| 949 | |B NATIONALLICENCE |F NATIONALLICENCE |b NL-gruyter | ||